News Allergan abandons women’s health sale plan as profit slumps Shares in Allergan fell after the company said it had swung to a loss in the last quarter of 2018, and forecast 2019 revenues below analyst expectations.
News UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac... Biotech hopes for IPO or big pharma deal to fund phase 3
News FDA rejects Allergan's fibroids drug, citing liver safety co... European regulators have already restricted use
News Remepy's hybrid Parkinson's therapy poised for phase 3 Remepy's Hybridopa therapy for Parkinson's, which combines an app with levodopa therapy, has shown efficacy in a phase 2 pilot study.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
